ReviewDrug design, development and therapy2020
Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.
Review in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 132 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer
Effects of Exercise Oncology Intervention in Fitness Capacity and Body Composition in Breast Cancer Survivals
Who cites it
132 citing papers in PubMed, 3 syntheses or guidelines pooled it, 223 citations in OpenAlex.
- Predictors of pathologic complete response in triple‑negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical and experimental medicine · 2026Pooled it
- Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Ultrasound-based radiomics for early predicting response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review with meta-analysis.La Radiologia medica · 2024Pooled it
- Safety and preliminary efficacy of adding tocilizumab to cisplatin/docetaxel for the treatment of locally advanced triple-negative breast cancer patients: prospective phase 1/2 clinical trial.Scientific reports · 2026Trial
- Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.Scientific reports · 2024Trial
- De-Escalation of Neoadjuvant Treatment for HER2-Positive Breast Cancer.International journal of cancer · 2026Review
- Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.Oncology letters · 2026Article
- Article
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Prediction of pathological complete response to neoadjuvant therapy in breast cancer integrating intratumoral and peritumoral delta radiomics with clinical features: a study based on multiparametric MRI.BMC medical imaging · 2026Article
- Nomograms Integrating Body Composition Metrics Predict Total Pathologic Complete Response after Neoadjuvant Systemic Therapy for Breast Cancer.Cancer research and treatment · 2026Article
- Neoadjuvant Chemotherapy for Male Breast Cancer: A Retrospective Cohort Study.Cancer medicine · 2026Article
- Novel Selective Anticancer Effect of Epididymis-Derived Extracellular Vesicles Against HCC38 and MCF-7 Breast Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Ki67 and Lymphovascular Invasion as Histopathological Predictors of Residual Cancer Burden After Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
- The Impact of Neoadjuvant Chemotherapy on Implant-Based Breast Reconstruction Outcomes.Plastic and reconstructive surgery · 2026Article
- Development and validation of an interpretable machine learning model for postoperative radiotherapy decision-making in ypN0 breast cancer after neoadjuvant chemotherapy: a real-world study.BMC medical informatics and decision making · 2026Article
- Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Dual-input spatio-temporal transformer model: Predicting the efficacy of NACT in breast cancer based on DCE-MRI images.iScience · 2026Article
- Locally advanced breast cancer is the number of dissected nodes after neoadjuvant chemotherapy important?Ecancermedicalscience · 2026Review
- Axillary response and diagnostic accuracy of imaging modalities after neoadjuvant chemotherapy for breast cancer (retrospective single center study).Frontiers in surgery · 2026Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.